» Articles » PMID: 33794850

Inflammatory Indexes in Preoperative Blood Routine to Predict Early Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy

Overview
Journal BMC Surg
Publisher Biomed Central
Specialty General Surgery
Date 2021 Apr 2
PMID 33794850
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The inflammation indexes in blood routine play an essential role in evaluating the prognosis of patients with hepatocellular carcinoma, but the effect on early recurrence has not been clarified. The study aimed to investigate the risk factors of early recurrence (within 2 years) and recurrence-free survival after curative hepatectomy and explore the role of inflammatory indexes in predicting early recurrence.

Methods: The baseline data of 161 patients with hepatocellular carcinoma were analyzed retrospectively. The optimal cut-off value of the inflammatory index was determined according to the Youden index. Its predictive performance was compared by the area under the receiver operating characteristic curve. Logistic and Cox regression analyses were used to determine the risk factors of early recurrence and recurrence-free survival.

Results: The area under the curve of monocyte to lymphocyte ratio (MLR) for predicting early recurrence was 0.700, which was better than systemic inflammatory response index (SIRI), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and systemic immune-inflammatory index (SII). MLR, tumour size, tumour differentiation and BCLC stage are all risk factors for early recurrence and recurrence-free survival of HCC. Combining the above four risk factors to construct a joint index, the area under the curve for predicting early recurrence was 0.829, which was better than single MLR, tumour size, tumour differentiation and BCLC stage. Furthermore, with the increase of risk factors, the recurrence-free survival of patients is worse.

Conclusion: The combination of MLR and clinical risk factors is helpful for clinicians to identify high-risk patients with early recurrence and carry out active postoperative adjuvant therapy to improve the prognosis of patients.

Citing Articles

The prognostic value of systemic inflammation response index in digestive system carcinomas: a systematic review and meta-analysis.

Niu Z, Lin L, Peng H, Zheng X, Wang M, Sun F BMC Gastroenterol. 2025; 25(1):34.

PMID: 39856542 PMC: 11761727. DOI: 10.1186/s12876-025-03635-2.


Construction of a random survival forest model based on a machine learning algorithm to predict early recurrence after hepatectomy for adult hepatocellular carcinoma.

Zhang J, Chen Q, Zhang Y, Zhou J BMC Cancer. 2024; 24(1):1575.

PMID: 39722042 PMC: 11670344. DOI: 10.1186/s12885-024-13366-4.


Development and validation of a prognostic nomogram including inflammatory indicators for overall survival in hepatocellular carcinoma patients treated primarily with surgery or loco-regional therapy: A single-center retrospective study.

Wang X, Xu J, Jia Z, Sun G Medicine (Baltimore). 2024; 103(50):e40889.

PMID: 39686498 PMC: 11651482. DOI: 10.1097/MD.0000000000040889.


The predictive value of serum inflammatory markers for the severity of cervical lesions.

Qin L, Zhang L BMC Cancer. 2024; 24(1):780.

PMID: 38943072 PMC: 11212428. DOI: 10.1186/s12885-024-12561-7.


Emerging Prognostic Markers in Patients Undergoing Liver Resection for Hepatocellular Carcinoma: A Narrative Review.

Panettieri E, Campisi A, De Rose A, Mele C, Giuliante F, Vauthey J Cancers (Basel). 2024; 16(12).

PMID: 38927889 PMC: 11201456. DOI: 10.3390/cancers16122183.


References
1.
Mano Y, Shirabe K, Yamashita Y, Harimoto N, Tsujita E, Takeishi K . Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Ann Surg. 2013; 258(2):301-5. DOI: 10.1097/SLA.0b013e318297ad6b. View

2.
Cucchetti A, Piscaglia F, Caturelli E, Benvegnu L, Vivarelli M, Ercolani G . Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol. 2008; 16(2):413-22. DOI: 10.1245/s10434-008-0232-4. View

3.
Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio G . Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006; 243(2):229-35. PMC: 1448919. DOI: 10.1097/01.sla.0000197706.21803.a1. View

4.
Hu B, Yang X, Xu Y, Sun Y, Sun C, Guo W . Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014; 20(23):6212-22. DOI: 10.1158/1078-0432.CCR-14-0442. View

5.
Wolber E, Jelkmann W . Thrombopoietin: the novel hepatic hormone. News Physiol Sci. 2002; 17:6-10. DOI: 10.1152/physiologyonline.2002.17.1.6. View